Supriya Lifescience Secures USFDA EIR With VAI Status for Lote API Facility
New Delhi: Active pharmaceutical ingredients (API) manufacturer Supriya Lifescience on Wednesday announced that the USFDA has issued an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification for its Lote facility in the state.
The inspection, conducted between February 2-6, 2026, concluded with the issuance of a Form 483 with one minor observation, Supriya Lifescience said in a statement.
The VAI classification enables Supriya Lifescience to maintain uninterrupted supplies of APIs to regulated markets such as the United States, Europe, and Japan.
"Successful closure of the USFDA inspection with this outcome reflects the strength of our quality systems and our consistent focus on regulatory excellence. It reinforces our position as a reliable API partner for global pharmaceutical companies and strengthens our ability to expand in regulated markets such as the US. We remain committed to maintaining the highest standards of quality and compliance across all our operations," Supriya Lifescience Executive Chairman and whole time director Dr Satish Wagh said.
